health care policy forecast: what to expect in 2018
TRANSCRIPT
Health Care Policy Forecast: What to Expect in 2018
Presented by :
Cybil Roehrenbeck and Michael Gaba
Overview: The Year Ahead
2017 Review & Political Landscape
Pending Legislation & Regulation
Top 10 Health Care Issues to Watch
Midterm Election
Looking Back
Affordable Care Act (ACA) Repeal
Regulatory Relief
FDA User Fee Reauthorization
Tax Reform
2017
Political Landscape
Sen. Orrin Hatch (R-UT), the Chairman of the Senate Finance Committee, will retire at the end of 2018.
Pending legislation and regulation
Budget
Children’s Health Insurance Program
(CHIP) Reauthorization & Medicare Extenders
ACA Insurance Market Stabilization
340B Medical Device Tax
Key Deadlines
Jan. 19, 2018
Budget Continuing Resolution
Expires
March 5, 2018
Congressional DACA Deadline
March 31, 2018
Temporary Funding for CHIP
Expires
Nov. 6, 2018
Midterm Elections
Children’s Health Insurance Program (CHIP)
GAME CHANGER: On Friday, January 5, the Congressional Budget Office (CBO) revised its estimate to reauthorize the CHIP program from $8B to $0.8 billion. This lower cost may give additional flexibility to pass a CHIP bill within the March 31 deadline, but political barriers remain.
Top 10 Health Issues to Watch in 2018
1. HHS Leadership
2. Medicare Extenders
3. Drug Prices & 340B Reform
4. Affordable Care Act (ACA) Taxes
5. ACA Repeal Part II
6. Regulatory Rollback
7. Opioid Crisis Funding
8. Food and Drug Administration (FDA) Reform
9. Medicare Payments
10. Medical Innovation Investment Opportunities
HHS Leadership
Alex Azar Former Deputy Secretary of HHS and President of Eli Lilly
CMS Leadership
Seema Verma Administrator
Kim Brandt Prin. Dep. Admin. for Operations
Demetrios Kouzoukas
Prin. Dep. Admin.
Alec Alexander Dep. Admin.
Center for Program Integrity
Medicare Extenders
Issues on Deck:
Delay of Medicaid DSH Cuts
Delay of 340B Cuts
Medicare Dependent Hospital Program and the Low-Volume Adjustment
Home Health rural add-on
Geographic payment cost index for physician payments
Ground Ambulance Add-Ons and ground ambulance payment modifications
Special needs plans (SNPs)
State Health Insurance Assistance Programs (SHIP)
Drug Prices & 340B
340B
Legal Administrative Legislative
CMS Reimbursement
Cuts Jan. 1
Affordable Care Act Taxes
1) Medical Device Tax
2) Over-The-Counter-Medications Tax
3) Health Insurance Tax
4) Employer Mandate
ACA Repeal Part II
Legislative Administrative
Budget Reconciliation (Part II) Medicaid Work Requirements
Graham-Cassidy Association Health Plans
Tax Delays Redefine Essential Health Benefits (EHB)
Individual Mandate Repealed Effective Jan. 1, 2018
Regulatory Rollback
1579 Regulatory Actions Withdrawn or Delayed in 2017
2018 Goal: Finalize three deregulatory actions for every new regulatory action
Trump Administration 2018 HHS Unified Agenda
I. More Effectively Meeting the Needs of Individuals II. Empowering Individuals and Communities Through
Reducing Regulatory Burden III. Maximizing the Impact of Every Federal Dollar Spent
Opioids
President’s Commission on Combating Drug Addiction and
the Opioid Crisis: REPORT
Congressional Oversight and Funding
HHS Funding Opportunities
Food and Drug Administration (FDA)
Drugs Oversight & Reforms
Devices
CMS Medicare Payments
Value-based Reimbursement Movement to Alternative Payment Models (APMs)
Merit-Based Incentive Payment System (MIPS)
Implementation Timeline
Medicare Access and CHIP Reauthorization
Act (MACRA)
Medical Innovation Investment Opportunities
Telehealth Health IT
Drugs & Devices
CMMI Payments
Mid-Term Election
34 Senate Seats 26D-8R
435 House Seats 238R-193D
Questions?
Contact Information
Cybil G. Roehrenbeck Shareholder Polsinelli PC
1401 Eye Street, N.W., Suite 800 Washington, D.C. 20005
202.777.8931 [email protected]
Michael Gaba Shareholder
Vice Chair, FDA Practice Group Polsinelli PC
1401 Eye Street, N.W., Suite 800 Washington, D.C. 20005
202.772.8496 [email protected]
real challenges. real answers. sm
Polsinelli provides this material for informational purposes only. The material provided herein is general and is not intended to be legal advice. Nothing herein should be relied upon or used without consulting a lawyer to consider your specific circumstances, possible changes to applicable laws, rules and regulations and other legal issues. Receipt of this material does not establish an attorney-client relationship. Polsinelli is very proud of the results we obtain for our clients, but you should know that past results do not guarantee future results; that every case is different and must be judged on its own merits; and that the choice of a lawyer is an important decision and should not be based solely upon advertisements. © 2016 Polsinelli PC. In California, Polsinelli LLP. Polsinelli is a registered mark of Polsinelli PC